Opens in a new tab

GRP Officially Becomes a Member of Japan Association for Diabetes Education and Care (JADEC)

Press Release

Document Link Here

GRP Officially Becomes a Member of JADEC
Date: April 30, 2025

We are pleased to announce that Global Regulatory Partners (GRP) has officially joined the Japan Association for Diabetes Education and Care (JADEC) as a supporting member.

This important milestone reinforces our commitment to expanding access to educational materials for patients, schools, and other institutions in need of Baqsimi® as an emergency-use medication.
Through this partnership, we aim to further promote awareness, preparedness, and rapid response in managing hypoglycemic emergencies.

At GRP, we remain dedicated to delivering innovative and safe products to patients in Japan.

Thank you for your continued support as we work to broaden our impact and strengthen our contributions to patient care.

Sincerely,
GRP Executive Members and Team

Related News

  • GLOBAL REGULATORY PARTNERS JAPAN JOINS THE TOKYO CHAMBER OF COMMERCE AND INDUSTRY (TCCI)

    Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Tokyo Chamber of Commerce and Industry (TCCI / 東京商工会議所), effective October 2026. GRP Japan will belong to the Minato Branch (港支部), one of TCCI’s 23 ward-based branches, strengthening the company’s connection with the local business community in Minato Ward.
    View More

  • Global Regulatory Partners Announces MHLW Approval of Aflibercept Biosimilar Prefilled Syringe in Japan

    Tokyo, Japan - October 26, 2026 - Global Regulatory Partners GK (GRP) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on October 13, 2026 for Aflibercept BS Solution for Intravitreal Injection Kit 40 mg/mL [GRP] (prefilled syringe (PFS) presentation), a biosimilar to EYLEA®¹ (aflibercept), for ophthalmic use.
    View More

  • GRP JAPAN JOINS THE JAPAN RADIOPHARMACEUTICALS ASSOCIATION

    Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.
    View More

  • Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan

    Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.
    View More